CA2323237A1 - Improved radiation therapy methods - Google Patents

Improved radiation therapy methods Download PDF

Info

Publication number
CA2323237A1
CA2323237A1 CA002323237A CA2323237A CA2323237A1 CA 2323237 A1 CA2323237 A1 CA 2323237A1 CA 002323237 A CA002323237 A CA 002323237A CA 2323237 A CA2323237 A CA 2323237A CA 2323237 A1 CA2323237 A1 CA 2323237A1
Authority
CA
Canada
Prior art keywords
analogues
aii
radiation therapy
therapy methods
angiotensin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002323237A
Other languages
French (fr)
Other versions
CA2323237C (en
Inventor
Kathleen E. Rodgers
Gere Dizerega
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southern California USC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA2659664A priority Critical patent/CA2659664C/en
Publication of CA2323237A1 publication Critical patent/CA2323237A1/en
Application granted granted Critical
Publication of CA2323237C publication Critical patent/CA2323237C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0819—Tripeptides with the first amino acid being acidic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/085—Angiotensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/14—Angiotensins: Related peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0644—Platelets; Megakaryocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/32—Angiotensins [AT], angiotensinogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Vascular Medicine (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention provides methods and kits for mitigating radiation induced tissue damage, improving the effectiveness of radiation therapy, to support bone marrow transplantation, and promoting megakaryocyte production and mobilization and platelet production, each method comprising the administration of an effective amount of angiotensinogen, angiotensin I(AI), AI analogues, AI fragments and analogues thereof, angiotensin II (AII), AII analogues, AII fragments or analogues thereof or All AT2 type 2 receptor agonists.
CA002323237A 1998-03-10 1999-03-08 Improved radiation therapy methods Expired - Fee Related CA2323237C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2659664A CA2659664C (en) 1998-03-10 1999-03-08 Improved radiation therapy methods

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US7738298P 1998-03-10 1998-03-10
US60/077,382 1998-03-10
US8126298P 1998-04-09 1998-04-09
US60/081,262 1998-04-09
US8367098P 1998-04-30 1998-04-30
US60/083,670 1998-04-30
US9009698P 1998-06-19 1998-06-19
US60/090,096 1998-06-19
US9021698P 1998-06-22 1998-06-22
US60/090,216 1998-06-22
US9995798P 1998-09-11 1998-09-11
US60/099,957 1998-09-11
PCT/US1999/005194 WO1999045945A1 (en) 1998-03-10 1999-03-08 Improved radiation therapy methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2659664A Division CA2659664C (en) 1998-03-10 1999-03-08 Improved radiation therapy methods

Publications (2)

Publication Number Publication Date
CA2323237A1 true CA2323237A1 (en) 1999-09-16
CA2323237C CA2323237C (en) 2009-05-19

Family

ID=27557165

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2659664A Expired - Fee Related CA2659664C (en) 1998-03-10 1999-03-08 Improved radiation therapy methods
CA002323237A Expired - Fee Related CA2323237C (en) 1998-03-10 1999-03-08 Improved radiation therapy methods

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA2659664A Expired - Fee Related CA2659664C (en) 1998-03-10 1999-03-08 Improved radiation therapy methods

Country Status (5)

Country Link
EP (1) EP1061937A1 (en)
JP (1) JP3728400B2 (en)
AU (1) AU744799B2 (en)
CA (2) CA2659664C (en)
WO (1) WO1999045945A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6730775B1 (en) 1999-03-23 2004-05-04 University Of Southern California Methods for limiting scar and adhesion formation
US7338938B2 (en) 1999-05-10 2008-03-04 University Of Southern California Methods for treating a patient undergoing chemotherapy
WO2002087504A2 (en) * 2001-05-01 2002-11-07 University Of Southern California Methods for inhibiting tumor cell proliferation
AU2002257970B2 (en) 2001-05-31 2007-08-02 Vicore Pharma Ab Tricyclic compounds useful as angiotensin II agonists
JP5823486B2 (en) * 2010-03-26 2015-11-25 ユニバーシティー オブ サザン カリフォルニア Method for treating combined radiation and heat damage
CA2795520C (en) 2010-04-06 2018-03-06 Synedgen Inc. Methods and compositions for treating wounds utilizing chitosan compounds
US20120071397A1 (en) * 2010-08-10 2012-03-22 University Of Southern California Methods for Hematopoietic Stem Cell Transplantation
EP2455388A1 (en) 2010-11-23 2012-05-23 LanthioPep B.V. Novel angiotensin type 2 (AT2) receptor agonists and uses thereof.
WO2013152291A1 (en) * 2012-04-05 2013-10-10 University Of Southern California Cell therapy technology to deliver radio-protective peptides
US8557958B1 (en) 2012-06-18 2013-10-15 Tarix Pharmaceuticals Ltd. Compositions and methods for treatment of diabetes
EP2897622B1 (en) * 2012-09-20 2021-04-21 Synedgen, Inc. Methods for treatment or prevention of damage resulting from radiation
US8633158B1 (en) 2012-10-02 2014-01-21 Tarix Pharmaceuticals Ltd. Angiotensin in treating brain conditions
US9333233B2 (en) 2014-02-25 2016-05-10 Tarix Pharmaceuticals Ltd. Methods and compositions for the delayed treatment of stroke
US20220257698A1 (en) 2019-08-02 2022-08-18 Lanthiopep B.V. Angiotensin type 2 (at2) receptor agonists for use in the treatment of cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE457055B (en) * 1986-08-18 1988-11-28 Ferring Ab TOPIC RADIATION GEL FOR MUKOSA CONTAINING VARIETY CONDUCTIVE SUBSTANCES
US5015629A (en) * 1989-06-26 1991-05-14 University Of Southern California Tissue repair
JPH09503205A (en) * 1993-09-24 1997-03-31 ザ ユニバーシティ オブ サザーン カリフォルニア Use of angiotensin II analogues in tissue repair
WO1997034627A2 (en) * 1996-03-19 1997-09-25 Societe De Conseils De Recherches Et D'applications Scientifiques S.A. Protection of hemopoietic cells during chemotherapy or radiotherapy

Also Published As

Publication number Publication date
CA2659664A1 (en) 1999-09-16
AU744799B2 (en) 2002-03-07
JP3728400B2 (en) 2005-12-21
AU2995799A (en) 1999-09-27
JP2002506042A (en) 2002-02-26
CA2323237C (en) 2009-05-19
WO1999045945A1 (en) 1999-09-16
EP1061937A1 (en) 2000-12-27
CA2659664C (en) 2013-05-07

Similar Documents

Publication Publication Date Title
WO2000002905A3 (en) Methods for accelerating bone and cartilage growth and repair
CA2323237A1 (en) Improved radiation therapy methods
WO2000053211A3 (en) Method of promoting myocyte proliferation and myocardial tissue repair
EP0781136A4 (en) Compounds and methods for the treatment of cancer
MY129189A (en) Prostaglandin agonists and their use to treat bone disorders
WO1999040106A3 (en) Use of angiotensin analogues for promoting erythropoiesis
AU6242298A (en) Methods for promoting healing of corneal resurfacing wounds
EP0911321A3 (en) Compounds for the treatment of osteoporosis
DE69924715D1 (en) USE OF ANGIOTENSIN ANALOGUE FOR THE PREPARATION OF A MEDICAMENT FOR INCREASING OVERLAPPING OF WHITE BLOOD CELLS AND MOBILIZING HAEMATOPOIETIC STEM CELLS AFTER CHEMOTHERAPEUTIC TREATMENT
WO1998058911A3 (en) Prostaglandin agonists
WO1999046285A3 (en) Method of promoting production of living tissue equivalents
WO1998033813A3 (en) Method for accelerating healing of thermal injuries
WO2002092013A3 (en) Methods for treating liver disease and liver damage with growth hormone and foxm1b
ATE335496T1 (en) ANGIOTENSIN II AND ANALOGUES FOR LIMITING SCARS AND ADHESION FORMATION
MXPA02001204A (en) Calcilytic compounds.
IL158433A (en) Toluene sulfonamide-containing anti-tumor composition and method of use thereof
WO2001043761A3 (en) Methods for treating and preventing damage to mucosal tissue
WO2001055176A3 (en) Methods for inhibiting smooth muscle cell proliferation
WO2002006308A3 (en) Methods for promoting dendritic cell proliferation or differentiation
WO2001044270A3 (en) Methods for treating and preventing diabetic complications by use of angiotensin-related peptides
EP0967276A3 (en) Anti-tumor agent comprising salmosin
PL336897A1 (en) Novel salts of bpc peptides, pharmaceutic compositions conatining them and method of obtaining such salts
WO2000059940A3 (en) Platelet-derived growth factor related gene and protein
DK0934342T3 (en) Composition containing chitosan
DE69734349D1 (en) TREATMENT OF BONE DRESS WITH ADRENOMEDULLIN

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20160308